CorFlow Therapeutics AG ("CorFlow") today announced that it is restructuring it's management team.
It is with great pleasure that CorFlow announces the arrival of Mr. Timothy Snyder as Chief Financial Officer (CFO). Tim joined the company in December 2018 and brings with him 30 years of experience as a finance professional. He started his career with the “Big Four” accounting firm of Deloitte in Columbus, Ohio (USA). After nine years as a practicing CPA, he went on to serve as Finance Director and CFO for a number of international companies in both the United States and in Europe. Before joining CorFlow, Tim served as the CFO of a Swiss stock-listed contract research organisation (CRO) which served pharmaceutical and biotech companies around the globe. Tim has significant experience in the design and implementation of financial systems including accounting, reporting, budgeting and cash management. He also brings a strong knowledge of corporate governance and general business administration which will help CorFlow through its next stages of growth.
Jon H. Hoem, CorFlow’s CEO and Co-Founder, said: “CorFlow’s business activities have grown to the point where we require a full-time financial executive, and Tim is the ideal fit for us. He has a wide range of experience and has a strong track record of building a financial organisation, with related control systems, from the ground up. Tim will also assist me with broader organisational matters and will be critical to our next rounds of financing planned for the coming years.”
Tim commented on joining the CorFlow team: “After getting to know Jon and the team in recent months, I couldn’t be more excited to build on what they have already achieved and help guide the company through its next phases of growth and success.”
Mrs. Blathnaid Feldman, VP of Regulatory Affairs and Quality Assurance (RAQA), has decided to leave the company to pursue other career objectives. As an interim solution, Mrs. Esther Gerteis, CorFlow's VP of Clinical, will take over Blathnaid's responsibilities until a replacement is found. The company has initiated a search for a permanent replacement for the VP RAQA - see the full job description here.
Jon commented on Blathnaid's decision: "I thank Blathnaid for her important contributions to the CorFlow vision and wish her continued success in her future career."
It is with great pleasure that CorFlow announces the arrival of Mr. Timothy Snyder as Chief Financial Officer (CFO). Tim joined the company in December 2018 and brings with him 30 years of experience as a finance professional. He started his career with the “Big Four” accounting firm of Deloitte in Columbus, Ohio (USA). After nine years as a practicing CPA, he went on to serve as Finance Director and CFO for a number of international companies in both the United States and in Europe. Before joining CorFlow, Tim served as the CFO of a Swiss stock-listed contract research organisation (CRO) which served pharmaceutical and biotech companies around the globe. Tim has significant experience in the design and implementation of financial systems including accounting, reporting, budgeting and cash management. He also brings a strong knowledge of corporate governance and general business administration which will help CorFlow through its next stages of growth.
Jon H. Hoem, CorFlow’s CEO and Co-Founder, said: “CorFlow’s business activities have grown to the point where we require a full-time financial executive, and Tim is the ideal fit for us. He has a wide range of experience and has a strong track record of building a financial organisation, with related control systems, from the ground up. Tim will also assist me with broader organisational matters and will be critical to our next rounds of financing planned for the coming years.”
Tim commented on joining the CorFlow team: “After getting to know Jon and the team in recent months, I couldn’t be more excited to build on what they have already achieved and help guide the company through its next phases of growth and success.”
Mrs. Blathnaid Feldman, VP of Regulatory Affairs and Quality Assurance (RAQA), has decided to leave the company to pursue other career objectives. As an interim solution, Mrs. Esther Gerteis, CorFlow's VP of Clinical, will take over Blathnaid's responsibilities until a replacement is found. The company has initiated a search for a permanent replacement for the VP RAQA - see the full job description here.
Jon commented on Blathnaid's decision: "I thank Blathnaid for her important contributions to the CorFlow vision and wish her continued success in her future career."
